This FDA-approved injectable drug is primarily used for weight loss in obese adults but also effectively improves blood sugar levels in people with type 2 diabetes
Tang Q, Zheng G, Feng Z, Chen Y, Lou Y, Wang C, et al
Furthermore, it was reported that this risk increases with the duration of exposure to GLP-1 receptor agonists, with the highest risk observed after 1.6 years
Globally and in Taiwan, MIS-C appears to have a higher prevalence, estimated at 2 cases per 100,000 children, compared to MIS-A [3]
The headaches , anxiety , and muscle pain reported with injectable GLP-1 drugs are largely absent from probiotic use
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases MHRA Drug Safety Update